Oral BPC-157 appears more relevant for localized effects in the digestive system because some preclinical research suggests stability in gastric conditions and interaction with gut tissue
This is the peptide controversy of 2026 and it's about to get much bigger
Specifically, BPC 157 inhibited the mRNA of inflammatory mediators (iNOS, IL-6, IFN, and TNF-), increased the expression of HSP 70 and 90, and antioxidant proteins (such as HO-1, NQO-1, glutathione reductase, glutathione peroxidase 2, and GST-pi) ( Further, we should appreciate the noted methodology point (i.e., the vascular failure obtained by retrobulbar L-NAME injection and by therapy counteracted, as specific major findings, and the normal intraocular pressurethe severe eye damage)
In terms of human research, one small 2024 study gave BPC-157 injections (10mg total) to 12 women with interstitial cystitis
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL 33.3 mcg total blend on a U-100 insulin syringe